The 2024 EASL Clinical Practice Guidelines highlight that first-line targeted therapies for HCC predominantly utilize multi-tyrosine kinase inhibitors (multi-TKIs), which exert anti-angiogenic effects primarily through VEGF receptor blockade while demonstrating ancillary activity against FGFR, TIE2, and MET pathways (3). This evidence concerns the gene MET and hepatocellular carcinoma.